肝脏疾病细胞铁死亡研究进展*

doi:10.3969/j.issn.1672-5069.2022.03.037

Abstract

Abstract: Objective Ferroptosis is a newly discovered mode of cell death, which is caused by the abnormal increase of intracellular iron ion levels, resulting in the imbalance of redox, lipid peroxidation of cell membrane, and finally cell death owing to cell membrane rupture. At present, the central link of ferroptosis is iron metabolism and reactive oxygen metabolism. Ferroptosis can affect the occurrence and development of a variety of diseases, such as neurodegenerative diseases, tumors, ischemia-reperfusion injury, immunoimbalance diseases, etc. Increasing numbers of studies have shown that the characteristics of ferroptosis, such as iron overload and accumulation of lipid reactive oxygen species, occur in the development many liver diseases. Ferroptosis can affect the progression of liver diseases by regulating the intracellular iron ion levels and lipid peroxidation degree.In this review, we put emphasis on the research progress of ferroptosis in liver diseases.

Key words: Liver diseases, Ferroptosis, Lipid peroxidation, Reactive oxygen species

Xue Qi, Xu Yayun, Li Jie. Ferroptosis in chronic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(3): 449-452.

References

[1] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2019, 4(5):389-398.
[2] 廖志武,王善青.我国2000-2019年主要热带病的流行与防治概况.中国热带医学, 2020, 20(3):193-201.
[3] 刘岩,苏琳.酒精性肝病基层诊疗指南(2019年). 临床肝胆病杂志, 2021, 37(1):36-40.
[4] 崔天盆,郑承红,陈杰,等. 细胞死亡方式及其清除. 中国免疫学杂志, 2014, 30(6):843-846.
[5] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5):1060-1072.
[6] Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A, 2016, 113(34):E4966-4975.
[7] Santana-Codina N, Mancias JD. Therole of NCOA4-mediated ferritinophagy in health and disease. Pharmaceuticals (Basel), 2018, 11(4):232-236.
[8] Hu CL, Nydes M, Shanley KL, et al. Reduced expression of the ferroptosis inhibitor glutathione peroxidase‐4 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurochem, 2019, 148(3):426-439.
[9] Bridges RJ, Natale NR, Patel SA. System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol, 2012, 165(1):20-34.
[10] Mou Y, Wang J, Wu J, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol, 2019, 12(1):34.
[11] Buijs M, Doan NT, Van Rooden S, et al. In vivo assessment of iron content of the cerebral cortex in healthy aging using 7-Tesla T2-weighted phase imaging. Neurobiol Aging, 2017, 53:20-26.
[12] Hu Z, Zhang H, Yang SK, et al. Emergingrole of ferroptosis in acute kidney injury. Oxid Med Cell Longev, 2019, 2019:8010614.
[13] Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis, 2019, 10(6):341-349.
[14] Qi J, Kim JW, Zhou Z, et al. Ferroptosisaffects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. Am J Pathol, 2020, 190(1):68-81.
[15] Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int, 2020, 40(6):1378-1394.
[16] Yang Y, Chen J, Gao Q,et al. Study on the attenuated effect of ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology, 2020, 445:152599.
[17] 王兆飞,管世鹤,陈礼文,等. 慢性乙型肝炎患者血清铁调素和铁代谢指标及体外 HBV 转染 Huh7 细胞铁调素水平变化. 实用肝脏病杂志, 2020, 23(2):183-186.
[18] Kuo CY, Chiu V, Hsieh PC, et al. Chrysophanol attenuates hepatitis B virus X protein-induced hepatic stellate cell fibrosis by regulating endoplasmic reticulum stress and ferroptosis. J Pharmacol Sci, 2020, 144(3):172-182.
[19] Pan Y, Tang P, Cao J, et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: Evidence of ferroptosis induction. Biochem Biophys Res Commun, 2020, 533(4):1512-1518.
[20] Lörincz T, Jemnitz K, Kardon T, et al. Ferroptosis is involved in acetaminophen induced cell death. Pathol Oncol Res, 2015, 21(4):1115-1121.
[21] Wang M, Liu CY, Wang T, et al. (+)-Clausenamide protects against drug-induced liver injury by inhibiting hepatocyte ferroptosis. Cell Death Dis, 2020, 11(9):781.
[22] Zhou Z, Ye TJ, DeCaro E, et al. Intestinal SIRT1deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis. Am J Pathol, 2020, 190(1):82-92.
[23] Zhou Z, Ye TJ, Bonavita G, et al. Adipose-specific lipin-1 overexpression renders hepatic ferroptosis and exacerbates alcoholic steatohepatitis in mice. Hepatol Commun, 2019, 3(5):656-669.
[24] Zhang Z, Yao Z, Wang L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Autophagy, 2018, 14(12):2083-2103.
[25] Sui M, Jiang X,Chen J, et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother, 2018, 106:125-133.
[26] Wang L, Zhang Z, Li M, et al. P53-dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation. IUBMB Life, 2019, 71(1):45-56.
[27] Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signalingpathway. Biomed Pharmacother, 2019, 109:2043-2053.
[28] Li Y, Jin C, Shen M, et al. Iron regulatory protein 2 is required for artemether -mediated anti-hepatic fibrosis through ferroptosis pathway. Free Radic Biol Med, 2020, 160:845-859.
[29] Kim H, Lee JH, Park JW. Down-regulation of IDH2 sensitizes cancer cells to erastin-induced ferroptosis. Biochem Biophys Res Commun, 2020, 525(2):366-371.
[30] Wang S, Li F, Qiao R, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano, 2018, 12(12):12380-12392.
[31] Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology, 2016, 63(1):173-184.
[32] Bai T, Lei P, Zhou H, et al. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. J Cell Mol Med, 2019, 23(11):7349-7359.
[33] Zhang X, Du L, Qiao Y, et al. Ferroptosis is governed by differential regulation of transcription in liver cancer. Redox Biol, 2019, 24:101211.

Ferroptosis in chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.
[2]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[3]	Cai Dongmei, Wu Wenjuan, Jiang Yilun, et al. Implication of hepatic fat fraction by CT angiography in patients with nonalcoholic fatty liver diseases and high-risk coronary plaque [J]. Journal of Practical Hepatology, 2022, 25(3): 383-386.
[4]	Zhou Ping, Yao Dengfu, Yao Min. Hepatocyte malignant transformation in circumstances of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 157-160.
[5]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[6]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[7]	Li Wei, Huang Yu, Zhong Jing, et al. Correlation of PNPLA3 rs738409 gene polymorphism to genetic susceptibility of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 227-230.
[8]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[9]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[10]	Lin Ning, Kong Ming, Duan Zhongping. Pathogenesis of sarcopenia in liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 301-304.
[11]	Feng Yu, Du Zhenyuan, Li Yanbin, et al. Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases [J]. Journal of Practical Hepatology, 2022, 25(1): 58-61.
[12]	Li Yaping, Zhai Song, Wang Yuan, et al. Mechanism of caffeic acid phenethyl ester protects L02 cells from palmitate-induced lipotoxicity in vitro [J]. Journal of Practical Hepatology, 2021, 24(6): 786-789.
[13]	Zhu Nannan, Jiang Xiaohong, Zhou Jiayan, et al. Serum uric acid levels and its clinical implications in patients with diabetes mellitus type 2 and concomitant metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(6): 839-842.
[14]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[15]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.